NEKTAR THERAPEUTICS
Pharmaceutical Preparations · 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA 94158
官方登記資料
0位追蹤者
1990成立於
關於 NEKTAR THERAPEUTICS
Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. The company developed the world's first inhalable non-injectable insulin, Exubera, which was awarded as the bronze award by Wall Street Journal for its technological breakthrough.
Source: Wikipedia
產業Pharmaceutical Preparations
總部455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA 94158
成立時間1990
狀態營運中
專利1230 項專利
POLYMER ENGINEERED FORMS OF COLONY STIMULATING FACTOR-1WO2026064439A1 · 2026
Method for enhancing cellular immunotherapyAU2020252569B2 · 2026
關鍵數據
法律資訊
| 法定名稱 | NEKTAR THERAPEUTICS |
|---|---|
| SEC CIK | 906709在 SEC EDGAR 上查看 ↗ |
| EIN | 94-3134940 |
| 產業代碼(SIC) | 2834 |
| 登記地址 | 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA 94158 |
| 狀態 | 營運中 |
來源: SEC EDGAR · 更新於 2026年10月15日
聯絡方式與連結
地點
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA 94158
這是你的公司嗎?
免費認領此頁面,即可新增標誌、產品、照片與職缺,並回覆評論。
認領此頁面